Welcome to Kenya Association of Pharmaceutical Industry


  Contact Us : info@kapikenya.org I Member Login

All Posts in Category: News & Events

KAPI WEEKLY BRIEF: 18TH – 22ND JAN. 2021

Executive Summary

The Kenya Association of Pharmaceutical Industry (KAPI) is a membership organization, established in the late 1960s, representing biopharmaceutical manufacturers (or their local representatives) that through research invent and develop medicines and technologies (e.g., Biopharmaceuticals, Vaccine Healthcare, Medical devices, Diagnostics) that significantly improve people’s lives. KAPI represents the industry voice and promotes efficiency in the pharmaceutical industry to ensure that medical products and healthcare technologies of the highest quality can be readily available for diagnosis, prevention and treatment of diseases.

Weekly Brief:

This is a roundup of news allied to the biopharmaceutical industry with a bearing on our mission to improve access to lifesaving health products and technologies for positive health outcomes.

  • Larger trials needed to assess efficacy of tocilizumab in managing COVID-19. This follows conflicting findings from a study done in Brazil on the same drug published in the British Medical Journal (BMJ). (Reuters)
  • The US Government under President Biden and VP Kamala Harris recommits to WHO and plans to engage in supporting COVAX platform to support access to COVID-19 vaccines by poor countries. (AP News | AP News)
  • The World Health Organization (WHO) welcomes proposal by the European Commission to establish a treaty on Pandemic Preparedness keen on mobilizing political commitment at such critical times. (Reuters)
  • Three COVID-19 vaccines under final review by WHO for emergency use approval (Reuters)
  • “Equal access” to coronavirus vaccines is failing poor countries (POLITICO)
  • With emergence of new COVID-19 variants, vaccine efficacy against the new variants have been a concern. A study by Pfizer/BioNTech confirms efficacy of their vaccine against the UK variant of the virus. (Financial Times | STAT)
  • Global leaders make calls to rethink global public health governance for research and development on the backdrop of a raging pandemic. (South Center)
  • African children are consistently excluded from cancer clinical trials leading to high burden of cancer with no established therapies for this population. They are the unseen and the unheard. (BMJ Global Health)
  • WHO Executive Board discusses for the first time the importance of implementing mental health and psychosocial support services and activities. This will be expedited by endorsing the updated mental health action plan 2013 – 2030. (Relief Web)
  • Antibiotics overuse among pediatric patients which is rampant is driving the spike in antibiotic-resistant ‘superbugs’ in children’s hospitals. (Business Insider | Infectious Disease Society of America)
  • Drop in vaccination causes surge in global measles cases and deaths (JAMA)
  • Monthly Malaria Prophylaxis cuts child deaths in Sub-Saharan Africa (JAMA)
  • Progress towards ending TB at risk (Development Policy Center)
  • Gritstone Oncology a biotech company working on cancer vaccines adds COVID-19 vaccine to its pipeline with the hope of developing a vaccine effective against the entire family of viruses. (Fierce Biotech)
  • Single COVID-19 vaccine doses not as effective as earlier hoped. Study in Israel finds out. (Guardian)
  • COVID-19 vaccine shots to cost $3 to $ 10 under the African Union vaccine plan (Reuters)
  • COVAX is ready to deliver vaccines, WHO officials tell WHO Executive Board – but Regulatory Approvals still lagging for key COVAX products (Health Policy Watch)
  • Independent panel on pandemic preparedness and response presented a report on WHO with findings showing the agency is powerless with need for more funding and reforms. (France 24 | WSJ)
  • Executive Board members of the WHO call for diversification and reform of the agencies funding mechanisms to avoid budget crisis as was witnessed when US withdrew. (Health Policy Watch)
  • Nations propose strengthening of local manufacture of medicines and other health technologies to improve access to medicines during 148th Session of the WHO Executive Board Meeting. (WHO)
  • Africa CDC opens up COVID-19 vaccines pre-order programme for 55 AU countries (CGTN)
  • FDA approves first monthly injectable to treat HIV infection (STAT)

Thank You!!!

Read More

KAPI WEEKLY BRIEF: 11TH – 15TH JANUARY 2021

15th January 2021

Executive Summary

The Kenya Association of Pharmaceutical Industry (KAPI) is a membership organization, established in the late 1960s, representing biopharmaceutical manufacturers (or their local representatives) that through research invent and develop medicines and technologies (e.g., Biopharmaceuticals, Vaccine Healthcare, Medical devices, Diagnostics) that significantly improve people’s lives. KAPI represents the industry voice and promotes efficiency in the pharmaceutical industry to ensure that medical products and healthcare technologies of the highest quality can be readily available for diagnosis, prevention and treatment of diseases.

Weekly Brief:

This is a roundup of news allied to the biopharmaceutical industry with a bearing on our mission to improve access to lifesaving health products and technologies for positive health outcomes.

  • World Health Organization (WHO) team of scientists arrived in Wuhan China on Thursday 14th January 2021 in plans to probe the origins of COVID-19. This comes after delays in being granted permission for the visit by the Chinese government. (The Hindu)
  • With the global COVID-19 pandemic still soaring, there have been a rise in reports of emergence of new variants of the virus. Some are associated with severe infections or rapid spread as has been noted with the South African and UK variants. Recently Kenya and the US also reported new variants. (Kenya – Nation Media; US – Financial Times)
  • German company Baxter Germany set to start the production of BioNTech/Pfizer Vaccine by early March (Reuters)
  • African Union (AU) secured an additional 270million doses of COVID-19 vaccines from Pfizer, AstraZeneca through the Serum Institute of India, and Johnson & Johnsons. (Reuters; The Presidency)
  • AstraZeneca filed for EU vaccine approval with additional information on safety, quality and efficacy. (Medical Express)
  • GlaxoSmithKline (GSK) and Vir Biotechnology are set to test their monoclonal antibody treatment for on mild to moderate COVID-19 patients within the first quarter of 2021. (Reuters)
  • Systems thinking and the application of systems thinking tools to real world problems is critical in the fight against Neglected Tropical Diseases (NTDs). (Yale Insights)
  • Progress made in the fight against superbug Acinetobacter baumannii through coupling of phages and antibiotics. (newsGP)
  • The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and Speak Up Africa launched the Africa Young Innovators for Health Awards on 11th January 2021. This award seeks to fuel innovation and help advance promising healthcare solutions in the continent. (SciDev Net; Young Innovators for Health Award)

Thank You!!!

Read More

KAPI New Year Message – 2021

In a day, we’ll be crossing over from a significantly life-changing year to the next. The year 2020 has been life-changing to all of us; work from home, masking, social distancing, job losses, and loss of loved ones among others. It’s been extraordinary how we’ve adapted to the changes, pivoted our systems to cope and weathered the storm. Regardless of this, the battle isn’t yet won. COVID-19 is still with us and we’ve got to comply with the recommended measures of washing hands, wearing masks, social distancing and avoiding unnecessary travels & gatherings where possible.

When the first case of COVID-19 was reported in March, our lives were turned upside down with anxiety and uncertainty at its peak. As an association rooted on our mission, to promote efficiency in the pharmaceutical industry to ensure that medical products and healthcare technologies of the highest quality can be readily available for diagnosis, prevention and treatment of diseases, we have pivoted and continued to discharge our mandate through alternative means. Our physical meetings morphed to virtual meetings, stakeholders’ engagements took place virtually with a renewed commitment to leverage on our different strengths for improved efficiencies among others.

In September during the World Patient Safety Week, in conjunction with the Pharmacy and Poisons Board (PPB), Ecumenical Pharmaceutical Network (EPN), Pharmaceutical Society of Kenya (PSK), National Nurses Association of Kenya (NNAK), Kenya Medical Association (KMA), Hospital Pharmacists Association of Kenya (HOPAK) and The Aga Khan University Hospital (AKUH), we revamped our commitment to improve access to quality, safe and efficacious medical products and technologies as a prerequisite for quality healthcare & patient safety anchored on empowered, competent and protected healthcare workers. It also became evident that to foster this commitment, there’s need to continually engage with stakeholders and share insights for continuous improvement of care. As an association, we pledge to carry this into the next year.

Our members from the outset of the pandemic took up responsibility to engage with and contribute to the national response in different fronts. At institutional level, they adopted containment measures to safeguard their employees, reviewed their supply chain dynamics to buffer the sector from stock outs that were speculated. At community level, they were at the forefront in supporting communities through donations both to their communities and to professional associations to safeguard the wellbeing of healthcare practitioners among others. On global stage, our member companies have taken lead to develop therapeutics and vaccines for COVID-19. These include vaccines that are currently in the pipeline by Pfizer, GlaxoSmithKline, Sanofi, Johnson & Johnson among others. These have been made possible by our common commitment as an industry to improve access to quality lifesaving healthcare products and technologies for a healthy populace. In one way or the other, you as a stakeholder have made it possible for us to get to this point and we appreciate you for that.

As we welcome a new year, having come to terms with our new normal it’s time to improve on our performance rooted on our commitment to safeguard the health of our people and improve access to quality, safe and efficacious healthcare products and technologies. To realize this, we know we can only dream so big and bank on your support to make it a reality. It’s because of this that we commit the New Year to a “Year of Redefining Collaboration in the Pharmaceutical Industry”.

In the coming year, we’ll be keen to revamp and establish new collaborative engagements with stakeholders; bring science behind the work we do as an industry closer to the people we do it for and derive value from it and most importantly do good for our communities. Good business is good for business and this will always be at the core of our work. Let’s walk the journey together.

Read More

Biopharmaceutical Companies Take Lead in COVID-19 Response in Kenya

As a membership organization driven by tenets of social responsibility and commitment to public health, in the wake of COVID-19 it is in our purview to drive a common agenda to flatten the curve of transmission, build concerted efforts to ensure uninterrupted supply of medicines, diagnostics and healthcare technologies.

George Onyango, Country Manager – GlaxoSmithKline handing over donation of surgical masks to KMPDU leadership

Additionally, our member companies have been in the forefront driving action through donations in kind and financially to curtail the economic impacts of this pandemic on the less fortunate in the society. Times of hardship are when you know your true compatriots and based on the responses we’ve seen among our members we are confident as a nation we’ll emerge victorious in the end. When we count our losses and learn from this pandemic, we hope we’ll have a robust, responsive and people-centric healthcare system.

During the peak infection period coupled with stringent containment measures our member companies were involved in different initiatives as outlined below:

  1. Johnson & Johnson – Through the Kenya COVID-19 Business Response Platform committed Kshs. 5 Million to the emergency response by the government in different interventions as was necessary through a common engagement platform.
  2. Reckitt Benckiser – Through the Kenya COVID-19 Business Response Platform donated products and services to the national response team to a tune of Kshs. 13 million i.e. Kshs. 10 million worth of soap and Kshs. 3.8 million for Media Tv for public awareness and sensitization.
  3. GlaxoSmithKline – Donated surgical masks worth Kshs. 3 million to frontline healthcare workers through the Kenya Medical Practitioners Pharmacists and Dentists Union (KMPDU) to contain infection of health workers following global shortage of PPEs.
  4. AstraZeneca – Donated 35,000 surgical masks to the government to equip healthcare workers in the different isolation facilities.
  5. Bayer East Africa – Provided free IEC materials and hand sanitizers. These included fliers and posters with relevant COVID-19 information to sensitize the public and communities within which we operate both to both the employees and members of the public. Donation of five (5) handwashing water tanks to the Kenyatta National Hospital (KNH) to encourage handwashing as a preventive measure against COVID-19. The company also supported Tenwek Hospital in Bomet County with assorted PPEs including masks and gowns as well as thermos-guns and hand sanitizers.
  6. Novartis – With COVID-19, attention on other medical conditions have been at stake. On this account, when the world was marking World Sickle Cell Disease, as part of contribution to health systems strengthening and promoting care to Sickle Cell Disease Patients, Novartis offered support to the Ministry of Health, Kenya in commemorating the day. The support went into development of guidelines for the management of sickle cell disease as reported by the Chief Administrative Secretary of Health, Dr Rashid Aman.
Bayer Team at Tenwek Hospital as they donated PPEs to the facility.

These among many other interventions that were coordinated by industry leaders played a key role in shaping the trajectory of the disease in the country.

Read More

Aspirin abuse likely to cause brain damage

Health experts have warned against arbitrary use of aspirin in managing high blood pressure.

Responding to an emailed inquiry by this writer, Dr Loise Nyanjau of the Ministry of Health (MoH) said low-dose aspirin increases the risk of brain haemorrhage.

Long regarded as a wonder drug in the management of heart diseases, it is emerging that aspirin has no role in the routine treatment of hypertension.

WebMD defines bleeding in the brain (brain haemorrhage) as a type of stroke and attributes 13 per cent of strokes to such bleeding.

A stroke occurs when an artery in the brain bursts. The resulting bleeding kills the brain cells.

When blood from trauma irritates brain tissues, it causes swelling. This, WebMD says, is known as cerebral oedema.

“The pooled blood collects into a mass called a haematoma. These conditions increase pressure on nearby brain tissue, and that reduces vital blood flow and kills brain cells.”

HEART DISEASES

Bleeding can occur inside the brain, between the brain and the membranes that cover it, between the layers of the brain’s covering or between the skull and the covering of the brain.

Dr Nyanjau, a medical officer at the cardiovascular diseases (CVD) desk in the Non-Communicable Diseases (NCD) Unit of MoH, based her comments on the Kenya National Guidelines for Cardiovascular Diseases Management 2018.

“Aspirin is used to prevent the occurrence of cardiovascular diseases such as heart attack and stroke (that often kill or cause permanent disability) by reducing the chances of a blood clot forming in vulnerable individuals,” Dr Nyanjau said.

She added, however, that not all hypertensives need aspirin, which is best for persons with prior history of cardiovascular disease like a heart attack or stroke.

The rationale here is that the benefit of preventing another heart attack or stroke outweighs the risk of bleeding.

PRESCRIPTION

Use of aspirin, Dr Nyanjau said, is considered for persons with very high risk of developing cardiovascular disease depending on the person’s risk of bleeding and following a discussion with their health provider.

Dr Juliet Makanga, a neuropharmacologist and lecturer at Kenyatta University’s School of Pharmacy, shared Dr Nyanjau’s view on discretionary use of aspirin.

“Regardless of its effect on blood pressure, studies have shown that low-dose aspirin effectively prevents cardiovascular events in patients,” she said.

“However, the benefits of aspirin in hypertensive patients in the prevention of cardiovascular events such as myocardial infarction, that is heart attack, must be balanced against the risk of bleeding in the gut and in the brain.”

She advised proper management and medical follow-up. “Low-dose aspirin is not for every patient, and only the physician, having compounded various patient parameters, is best placed to make the decision,” she said.

RED FLAG

Kenya Network of Cancer Organisations chairman David Makumi noted that some studies have shown that aspirin also protects against colon cancer.

“However, the long-term side effects like bleeding in the stomach outweigh the decision to use it for colon cancer prevention,” he said.

In spite of the warnings, the reality on the ground is different, with Nairobi chemists dishing out low-dose aspirin over-the-counter without prescription.

CNN first raised the red flag on low-dose aspirin last September 17 when it reported three research findings in the New England Journal of Medicine.

The studies showed that “a daily low-dose aspirin regimen provides no significant health benefits for healthy older adults. Instead, it may cause them serious harm.”

It is “a waste of money for healthy older adults. At worst, it may raise their risk of internal bleeding and early death,” the international TV station said.

Perhaps due to the sensitivity of the subject and the clout of big pharma, the researchers fell short of telling healthy adults to stop routine ingestion of aspirin.

RESEARCH

Instead, they said: “Always consult your doctor before starting or stopping any medication” — a tall order in Kenya, where astronomical healthcare costs force patients to choose over-the-counter shortcuts.

Earlier in 2017, Sayer Ji of GreenMedInfo cited a Dutch study published in the journal Heart, which found that, “among 27,939 healthy female health professionals (average age 54) randomised to receive either 100 mg of aspirin every day or a placebo, the risk of gastrointestinal bleeding outweighed the benefit of the intervention for colorectal cancer and cardiovascular disease prevention in those under 65 years of age”.

Heart is a British international peer reviewed journal that keeps cardiologists up to date with important research advances in cardiovascular disease.

While the Kenya Health Policy 2014-2030 seeks to attain the highest possible standard of health in a manner responsive to the population’s health needs, by among other things, halting and reversing the rising burden of NCDs, unregulated use of low-dose aspirin is proving to be counterproductive.

Read More

KAPI confirms commitment to affordably deliver Non-Communicable Diseases medicines

The Kenya Association of Pharmaceutical Industry (KAPI) has expressed its commitment to continue facilitating a progressive reduction in the cost of Non communicable diseases (NCDs) medicines locally.

In a swift response to a public call by President Uhuru Kenyatta to international pharmaceutical firms, to reduce the cost of NCD medicines, KAPI, has confirmed ongoing efforts to affordably deliver essential medicines in Kenya. The efforts, are rolling out under a stakeholder initiative dubbed: Access Accelerated.

Alongside the initiative, the Association, comprising of leading international and local pharmaceutical firms, is also collaborating with the Ministry of Health to address non-tariff barriers affecting the pricing of medicines in the local market.

KAPI Chairperson, Dr. Anastasia Nyalita said the Association’s members have been undertaking public awareness programmes geared at educating Kenyans to exercise healthy living and preventive strategies as the most cost-effective measures against disease; especially lifestyle NCDs.

Speaking from New York, when he addressed a plenary session on the prevention and control of NCDs at the ongoing 73rd session on United Nations General Assembly in New York, last Thursday, President Kenyatta said access to essential medicines and technologies is key  for effective management of NCDs.

“I call on non-state actors including the pharmaceutical industries and private health service providers to partner with governments to bring down costs of treatment through fair pricing and ethical practices,” said President Kenyatta.

The President  said Kenya aims to guarantee access to quality NCD care through an integrated  primary health care approach  that emphasizes preventive and promotive  health intervention  that encourages the adoption of healthy lifestyles.

Additionally, said the Head of State, the government has committed itself to investing in additional and sustainable domestic financing to halt and reverse the burden of NCDs.

 

“To this end, we are embracing strategic partnerships and harnessing innovations from the private sector and other non-state actors in the entire continuum of NCDs,” he said

According to KAPI Chairperson, Dr. Anastasia Nyalita, the Association is playing a leading role in the local rollout of the global Access Accelerated initiative. Access Accelerated is a first-of-its-kind, multi-stakeholder collaboration focused on improving NCD care.

“KAPI, is working closely with the Ministry of Health among other stakeholders to address causative factors to the local cost of essential medicine and other pharmaceutical products, Dr Nyalita said. She added that, “Channel inefficiencies and excessive markup charges which contribute immensely to the unsustainable cost of medicine are currently under review.”

Launched at last year’s World Economic Forum in Davos Switzerland, Access Accelerated is an initiative spearheaded by twenty-two leading biopharmaceutical companies that have joined hands to advance the access to non-communicable (NCD) prevention and care agenda in low and lower-middle income countries including Kenya.

The ‘Access Accelerated’ programme, Nyalita said is already providing much needed impetus to facilitate sustainable NCD management.

 

Access Accelerated companies operating in Kenya include: Bayer, Bristol-Myers Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Merck, MSD, Novartis, Pfizer, Roche and Sanofi, among others.

“At KAPI, we wish to confirm our member companies’ commitment to affordably deliver NCD medicines in Kenya as and we look forward to partnering with the government as we seek to foster a conducive environment to ensure that we reduce mortality incidents associated with NCD diseases,” Nyalita said and added: “The call by President Kenyatta will further provide a good platform to crystalize Access Accelerated goals which are squarely aligned to the Big Four Agenda on Universal Health Care.”

The goal of Access Accelerated, in partnership with the World Bank Group and the Union for International Cancer Control (UICC), is to work towards the United Nations Sustainable Development Goal (SDG) target to reduce premature deaths from NCDs by one-third by 2030.

“Through the commitment and expertise of the Access Accelerated partners, we will work towards a shared vision where no person dies prematurely from a preventable, treatable disease,” said Ian Read, Chief Executive Officer of Pfizer and President of The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), on behalf of the initiative last year, adding that: “If the current trend in NCDs in low- and lower-middle income countries is not reversed, there is a real possibility we will undermine the progress we have made in health around the world. To reach our goal, we need to catalyze new partnerships, learn quickly and advance the resources and knowledge that will enable countries to tackle NCDs.”

 

In New York, President Kenyatta called on the international community to consider putting in place an incentive fund to stimulate the development of national NCD and mental health interventions and policy coherence for low and middle-income countries.

He said under the  Big-4 pillar , Universal Healthcare has prioritized early diagnosis, screening and treatment of chronic NCDs.

Kenya continues to make tremendous progress in implementing the 22 political commitments agreed upon seven years ago  aimed at a 25 per cent reduction in premature mortality occasioned by NCDs in 2025.

The President  said Kenya’s success in this regard has been achieved through the domestication of the previous political declaration that adapted the global action plan for the prevention and control of NCDs in the national development blue print.

Building on long-standing individual company investments in global health, Access Accelerated is addressing a variety of access barriers to NCD prevention, treatment and care. Efforts will be evaluated with the support of independent experts at Boston University to establish a framework for progress, measure effectiveness and deliver ongoing reporting.

With the World Bank Group, the initiative will identify solutions to address financing, regulatory and service delivery barriers at country level. Additionally, the World Bank Group is conducting pilots in primary care to improve NCD outcomes in several countries.

Read More

Tale of old man in Indian shops- Dr. Vijai Maini,MD Surgipham Ltd.

In 1897, a big ship docks in Mombasa from India. An Indian man gets off, stays a couple of years, finds Kenya too wild and gets on another ship and sails back to India. But the call of Africa doesn’t abate so he comes back in 1910, sets base and then invites some cousins over from India to join him.

One of the cousins who came is Vijai Maini’s grandfather.

The same Vijai who studied pharmacy in the UK and came back to start the very successful Surgipharm which now has an annual turnover of Sh700 million.

He started his company when he was 40 years, but before that he was playing badminton professionally and collecting a forest of trophies which he shows JACKSON BIKO in his boardroom in their offices in Westlands.

At 74 years, he reminisces about the young Vijai in sports, the current Vijai who has lived his life and raised his children in a way he is proud of.

Describe to me how it feels like to be 74 years old.

(Laughs) Well, it’s gratifying. (Pause) I played badminton until I was 40 years old and then I couldn’t play anymore because at that age, your energy levels are going down. I woke up and said, ‘I have to do something else with my life. So I started this business on a 4,000 square feet rental room in town.

Are you generally better at this age than you were at, say, 45?

I think one reasons better. You tend to be less aggressive, but at the same time you take less risks in business. The few you take pay off, some don’t. But I’m still very passionate, I have no intention of retiring.

What dreams do you have left that you plan to achieve now?

Well, my dream now is that this business that I created continues and thrive. The dream has always been to maintain the ethics of the business which is big for me. The drugs I sell are drugs that my own family would take. I have always prided myself to do things by the book and I would like that to be a dream that continues.

How is the experience of being a father different from being a grandfather?

We have a saying in our community: you love interest more than the capital. (Chuckles). The capital here is your children and the interest is your grandchildren.

When you have children, you’re so engrossed in trying to make your living and raising them. You don’t spend as much time with them because you are building something for yourself and for them. But with grandchildren, you have mellowed a bit and you have more time.

You tend to spoil them more than you did your children because anyway the responsibility to raise them is not mine. My responsibility was with my children and I already raised them so it’s their turn now. So yes, it’s a joy.

I have been blessed. I grew up in a joint family environment and my children grew up in the same joint family.

What is a joint family?

We’ve got four generations under one roof. When my sons grew up, there were four generations under one roof. My grandchildren until recently have grown with four generations under one roof with my mother who passed away three years ago at the age of 94.

Obviously, there are great advantages in having four generations under one roof in terms of cohesion but in terms of privacy, how does that work out especially when you are married and some people just can’t get along and they have to run into each other in the kitchen every day?

(Laughs) Privacy is not that much of a problem because we have been lucky to have reasonably sized accommodation. But generally it’s a give and take.

It’s usually the women who have to get more used to each other than the men. For instance, for the wives sharing a kitchen might not be the easiest thing. My mother was always the best cook and when my wife came in, she had to sort of get used to the way of life. But having been brought up in that environment, living with your grandfather, the uncles and the aunts sort of thing, it has just come naturally to me. It has not been difficult.

Now that you are here, an Indian patriarch, I might as well ask you this. How does the Indian community intend to integrate with the rest when they congregate as a community in specific areas away from the rest? Is this ever a need?

Integration comes in on the outside life, not where you live. It comes in when you’re a member of a private club or at school. I think a lot of integration happens in schools now more than ever. They don’t see colour. All my sons went to St Mary’s and they had more local Kenyan friends than Indian friends. My eldest is very good friends with an indigenous Kenyan, they ended up in the same university in the UK and he came back also and this guy has a very senior post in Standard Chartered.

What shakes your confidence now, at 74 years of age?

(Pause) Irregular business practices. The business practices now are not really what they were. In recent years, there has been a disturbing level of corruption that I’m not used to as a businessman. This is new to me, this is not how we have been doing business.

Sometimes when I visit an Indian shop, I see a very elderly Indian man seated at a small desk at the back, hunched over a stack of papers, poking at a calculator. An old man, probably 100 years old. I always wonder, why does that guy still come to the shop? Is it to keep his brain alive? Is it that that’s all he has done his whole life and knows nothing else? What’s his motivation? What’s your motivation to keep coming here at 74?

(Chuckles) So take me for example, I started in healthcare and I have never diverted from it. All profits made here have gone back into the business to build it. I have not had the desire to say ‘OK now let me go and start a hotel or put up my own buildings.’ I still rent here. I would rather keep the money in stocks and develop the business.

When you put everything in one thing, you want to preserve it. There is a bicycle shop in River Road started in the 1950s. The owners have diversified into the hotel industries in a big way but the old man, the owner, never sits in those many hotels. He sits in that shop where he started. This is a question of belief. Or luck.

When was the last time you were broke?

I cannot remember. (Laughs)

Uhm, 1969, probably?

(Chuckles loudly) No. I’ve been lucky. In the sense, I suppose I came into this world fortunately. My family has always been privileged, fortunately.

 

 

Read More

KENYA FEATURES PROMINENTLY IN GLOBAL PHARMACEUTICAL INDUSTRY REPORT

…As the global pharmaceutical industry advocates for even greater collaboration as critical to future global health progress

The International Federation of Pharmaceutical Manufacturers & Associations IFPMA has launched a report detailing milestones achieved in the health sector worldwide over the last 50 years.

The report launched today features Kenya as a key player in the formal pharmaceutical space in Sub-Sahara Africa.

Notably, the report by IFPMA affiliate –Kenya Association of Pharmaceutical Industry (KAPI)- highlights Kenya’s support for an ongoing World Health Organisation (WHO) pilot trial on a malaria vaccine scientifically code named RTS,S. RTS,S is an injectable vaccine that provides partial protection against malaria in young children.

Alongside Ghana and Malawi, Kenya has partnered with WHO in the Malaria Vaccine Implementation Programme (MVIP) that will make the RTS,S vaccine available in selected areas of the three countries. The two year clinical trial is expected to provide initial insights on the programmatic feasibility of delivering the RTS,S/AS01 vaccine (trade name Mosquirix™) in real-life settings and on the safety profile of RTS,S in the context of routine use.

Speaking when she confirmed the local launched of the IFPMA “50 Years of Global Health Progress” report, KAPI Chairperson Dr. Anastasia Nyalita said the report traces global health progress over the past 50 years. The report also catalogues the pioneering collaborative role the research-based biopharmaceutical industry has played not only to deliver prevention and treatment, but to strengthen health systems around the world.

“At KAPI, we salute the role played by our global affiliate IFPMA in collating a report that advances the body of knowledge on the role of pharmaceutical industry in development here in Kenya and beyond,” Dr. Nyalita said.

The report reviews some of the research-based biopharmaceutical industry’s major scientific advances, as well as acknowledging challenges the industry faces and areas of unfinished business. The industry’s track record of partnerships over recent decades demonstrates what can be achieved by uniting governments, civil society and business. The report concludes with a commitment to continue to innovate and partner with a shared goal to deliver better health for everyone, everywhere.

IFPMA President, Mr. Ian Read, who is also the Chairman and CEO of Pfizer in a global communique noted that advances in both prevention and treatment of disease have transformed healthcare. “Vaccines are widely recognized as the simplest, most cost-effective way to save lives. HIV/AIDS, once fatal, can now be treated as can many cancers. Cardiovascular disease sufferers benefit from simple-one-a-day solutions. We can now cure Hepatitis C. We have an experimental vaccine for Ebola,” he noted.

“The industry joined the earliest global health partnerships such as, in the 1970s, the Expanded Program on Immunization and, in the 1980s, the polio eradication and smallpox initiatives. These have been followed by partnerships as diverse as DNDi, MMV, Global Fund for AIDS, TB and Malaria, GAVI, the Vaccine Alliance, MPP, and, more recently, CEPI and Access Accelerated. “While the biopharmaceutical industry has been a key player in this progress, none of it would have been accomplished without partnerships. From patient advocates to our biotech and academic partners to individual governments, innovation is only as impactful as the partnerships that support it,” added Ian Read.

Partnerships are now the norm and the Sustainable Developments Goals serve to galvanize greater collaboration to confront new and remaining challenges as many people still lack access to essential health services, such as family planning, child immunization, antiretroviral therapy to combat HIV and AIDS, tuberculosis treatment, clean water and sanitation. Health systems struggle to respond effectively to burgeoning rates of non-communicable diseases; too many people still die prematurely from preventable diseases.

“Despite tremendous progress much more needs to be done to bring the fruits of our innovation to all. The research-based biopharmaceutical industry has learned that global health is about much more than medicines and vaccines – it requires building and supporting strong health systems, delivering education to communities to promote prevention, strengthening standards and regulations and creating innovative finance models. We will continue to evolve, learn and pioneer ways to do more to reach all patients. To do this we’ll need partnerships of all kinds to take on the challenges of Universal Health coverage (UHC). We need to continue to build bridges between key actors across the health system. More dialogue and action are musts” says IFPMA Director General, Thomas Cueni.

On the occasion of the 71st World Health Assembly and to celebrate its 50-year anniversary, IFPMA hosted an event on 23rd May in Geneva which featured a top-level panel to discuss priorities in delivering better health for everyone, everywhere.

Read More